Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378090 | 0.84 | HTR2C (0.61) | HTR2CMEN1KMT2A | |
| SCHEMBL6984602 | 0.82 | HTR2C (0.55) | HTR2CACHEKDM4EALDH1A1MEN1 | |
| SCHEMBL27543508 | 0.82 | HTR2C (0.55) | HTR2CACHELDHAMEN1KMT2A | |
| SCHEMBL2693403 | 0.80 | ACHE (0.63) | ACHELDHAKDM4EHPGDSALDH1A1 | |
| SCHEMBL9823334 | 0.80 | HTR2B (0.73) | ACHEKDM4EHPGDSALDH1A1HTR2B | |
| SCHEMBL3535941 | 0.79 | ACHE (0.58) | ACHEKDM4EHPGDSALDH1A1HTR2B | |
| SCHEMBL2691637 | 0.79 | ACHE (0.61) | HTR2CACHEKDM4EHPGDSALDH1A1 | |
| SCHEMBL3536997 | 0.79 | ACHE (0.66) | HTR2CACHEKDM4EHPGDSALDH1A1 | |
| SCHEMBL2545992 | 0.79 | ACHE (0.61) | ACHEKDM4EHPGDSALDH1A1HTR2B | |
| SCHEMBL6183496 | 0.79 | ACHE (0.66) | ACHEKDM4EHPGDSALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | claimed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | claimed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | claimed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | claimed |
| WO-2023170024-A1 | CAMK2 MODULATORS AND THEIR USE IN MEDICINE | UNIVERSITY OF COPENHAGEN (DK) | 2023-09-14 | — | — | WO | disclosed |
| US-20200392161-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRÖDINGER, INC. | 2020-12-17 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0591786-B1 | Photosensitive composition | FUJI PHOTO FILM CO LTD (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0591786-A2 | Photosensitive composition | FUJI PHOTO FILM CO., LTD. (JP) | 1994-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392161-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | HTR2C 4373/4885ACHE 4815/4885LDHA 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.